Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic Substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTN
Previous Symbol
CUSIPN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares203,060,000
Market Cap$0.00
OptionableNot Optionable
Palatin Technologies (NASDAQ:PTN) Frequently Asked Questions
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the NASDAQ under the ticker symbol "PTN."
How were Palatin Technologies' earnings last quarter?
Palatin Technologies, Inc. (NASDAQ:PTN) released its quarterly earnings data on Thursday, September, 13th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The firm had revenue of $20.62 million for the quarter, compared to the consensus estimate of $6.03 million. View Palatin Technologies' Earnings History.
What is the consensus analysts' recommendation for Palatin Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.
Has Palatin Technologies been receiving favorable news coverage?
News stories about PTN stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Palatin Technologies earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include IDEXX Laboratories (IDXX), IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and ImmuCell (ICCC).
Who are Palatin Technologies' key executives?
Palatin Technologies' management team includes the folowing people:
- Dr. John K. A. Prendergast Ph.D., Co-Founder & Non-Exec. Chairman (Age 64)
- Dr. Carl Spana Ph.D., Co-Founder, Pres, CEO & Director (Age 56)
- Mr. Stephen T. Wills CPA, MST, CFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec. (Age 61)
- Burns McClellan, VP of Investor Relations
- Dr. Johna Lucas M.A., M.D., F.A.C.O.G., Chief Medical Officer
How do I buy shares of Palatin Technologies?
Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Palatin Technologies' stock price today?
One share of PTN stock can currently be purchased for approximately $0.8030.
What is Palatin Technologies' official website?
MarketBeat Community Rating for Palatin Technologies (NASDAQ PTN)
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
